Resapp Health

Resapp Health Gross Profit

The Gross Profit of Resapp Health (RAP.AX) as of Nov 2, 2026 is 2.51 M AUD. In the previous year, Gross Profit was 69,731.00 AUD — a change of 3,502.41% (higher).

Gross Profit

2.51 MAUD

YoY

3,502.41%

Last updated:

Gross Profit of Resapp Health is 2022 2.51 M AUD. Gross Profit of Resapp Health was 2021 69,731.00 AUD. It decreases by 3,502.41% higher compared to the previous year.

The Resapp Health Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2006
105,013.00 AUD
Jan 1, 2007
546,892.00 AUD
Jan 1, 2009
502.00 AUD
Jan 1, 2012
2,108.00 AUD
Jan 1, 2013
50.00 AUD
Jan 1, 2021
69,731.00 AUD
Jan 1, 2022
2.51 M AUD
The Resapp Health Gross Profit history
YEARGross ProfitYoY
2.51 MAUD+3,502.41%
69,731.00AUD+139,362.00%
50.00AUD-97.63%
2,108.00AUD+319.92%
502.00AUD-99.91%
546,892.00AUD+420.79%
105,013.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Resapp Health Revenue

Resapp Health Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
0.00 AUD
-7.62 M AUD
-6.53 M AUD
Jan 1, 2019
0.00 AUD
-8.27 M AUD
-5.44 M AUD
Jan 1, 2020
0.00 AUD
-9.63 M AUD
-8.47 M AUD
Jan 1, 2021
69,731.00 AUD
-8.11 M AUD
-6.77 M AUD
Jan 1, 2022
2.51 M AUD
-6.94 M AUD
-7.10 M AUD
Jan 1, 2023
0.00 AUD
-2.50 M AUD
-2.49 M AUD
Jan 1, 2024
0.00 AUD
-1.97 M AUD
-1.89 M AUD
Jan 1, 2026
0.00 AUD
-2.13 M AUD
-3.28 M AUD

Resapp Health Margins

Resapp Health stock margins

The Resapp Health margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Resapp Health. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Resapp Health.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
100.00 %
- %
- %
Jan 1, 2019
100.00 %
- %
- %
Jan 1, 2020
100.00 %
- %
- %
Jan 1, 2021
100.00 %
-11,628.98 %
-9,714.47 %
Jan 1, 2022
100.00 %
-276.39 %
-282.48 %
Jan 1, 2023
100.00 %
- %
- %
Jan 1, 2024
100.00 %
- %
- %
Jan 1, 2026
100.00 %
- %
- %

Resapp Health Stock analysis

What does Resapp Health do? ResApp Health Ltd is an Australian company that focuses on the development of digital diagnostic and treatment solutions in the field of respiratory diseases. The company was founded in 2014 by Tony Keating and Philippa Lewis, both of whom have significant experience in the medical technology industry. The company aims to improve and simplify the diagnosis of respiratory diseases by developing a diagnosis based on cough and breath sounds. To achieve this, the company has developed an intelligent system based on machine learning and artificial intelligence that analyzes individual sound waves and provides an accurate diagnostic capability. ResApp Health's business model is based on the development of digital diagnostic and treatment solutions in the field of respiratory diseases, which are offered through various distribution channels. The company offers both mobile apps and clinical diagnostic systems. ResApp Health operates in various divisions at different levels. On the one hand, the company conducts research and development to continuously improve its products. On the other hand, it works closely with clinicians, scientists, and other industry experts to enable the best possible patient treatment. Products offered by ResApp Health include digital diagnostic systems in the field of respiratory diseases that function based on cough and breath sounds. The products are offered for use in both clinical practice and at home to enable fast and accurate diagnosis. Another important area in which ResApp Health operates is the treatment of respiratory diseases. The company offers digital therapy platforms tailored to the individual needs of patients, enabling improved therapy. ResApp Health has already achieved a number of important milestones. For example, in 2016, the company received CE marking for its digital diagnostic system, and in 2017, it completed a clinical study that demonstrated the system's high accuracy in diagnosing respiratory diseases. Overall, ResApp Health has great potential to play an important role in the field of diagnosis and treatment of respiratory diseases in the future. With a strong focus on research and development and close collaboration with industry experts, the company will continue to offer innovative solutions to improve patient health. Resapp Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Resapp Health stock

Gross Profit of Resapp Health is 2.51 M AUD in 2022.

Gross Profit of Resapp Health changed from 69,731.00 AUD to 2.51 M AUD, representing a 3,502.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit Resapp Health since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's Resapp Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Resapp Health

All Key Metrics — Resapp Health